Limits...
Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma.

Xu Y, Peng Z, Li Z, Lu M, Gao J, Li Y, Li Y, Shen L - BMC Cancer (2015)

Bottom Line: There was no statistical difference between c-Met expression and clinical features except sex and tumor location.Survival analysis documented that the overexpression of c-Met predicted a worse prognosis (OS: 253 d vs 422 d, P = 0.011).The overexpression of c-Met may predict a worse efficacy of anti-EGFR therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, FuCheng Road 52, HaiDian District, Beijing, China. xyystella@163.com.

ABSTRACT

Background: c-Met, one of current potential hot targets, has been suggested as a potential tumor marker in the development of esophageal squamous cell carcinoma (ESCC). Our aim was to investigate the expression of c-Met in advanced esophageal squamous cell carcinoma in four phase II trials who had tumor tissues from archival in our center and analyze the correlations between c-Met expression and clinical features.

Methods: Ninety patients with advanced ESCC who were admitted to the phase II clinical trials in the Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute from March 2007 to March 2014 were finally eligible for present study and the corresponding tissues and clinical data were collected. The expression of c-Met in the tissue samples was detected by immunohistochemistry (IHC). c-Met overexpression was defined as ≥ the median value of H-score. Kaplan-Meier and Cox multivariate regression were conducted to evaluate the relationship between c-Met expression and ESCC survival.

Results: The overexpression of c-Met is 43.3% in advanced ESCC. There was no statistical difference between c-Met expression and clinical features except sex and tumor location. Survival analysis documented that the overexpression of c-Met predicted a worse prognosis (OS: 253 d vs 422 d, P = 0.011). In the group treated with chemotherapy combined with anti-EGFR drugs, patients with lowexpression of c-Met had a better OS than those with overexpression of c-Met (OS: 577 d vs 232 d, P = 0.007).

Conclusions: c-Met may be an independent prognostic factor in advanced ESCC. The overexpression of c-Met may predict a worse efficacy of anti-EGFR therapy.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier survival curves of patients with ESCC according to treatment and c-Met expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4307685&req=5

Fig4: Kaplan-Meier survival curves of patients with ESCC according to treatment and c-Met expression.

Mentions: In this study, 25 patients received chemotherapy of taxol and cisplatin (TP) plus nimotuzumab, 55 patients received chemotherapy of TP alone, and 10 patients received other chemotherapies. In c-Met overexpression group, OS of patients who received TP plus nimotuzumab was not different from that of patients who received TP alone (232d vs 258d, P = 0.221). Similar results were obtained in c-Met low-expression group (577d vs 422d, P = 0.152). In TP plus nimotuzumab group, the OS of patients with c-Met low-expression was significantly better than those with c-Met over-expression (577d vs 232d, P = 0.007). In TP alone group, no statistical significance was found (422d vs 258d, P = 0.076) (Figure 4).Figure 4


Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma.

Xu Y, Peng Z, Li Z, Lu M, Gao J, Li Y, Li Y, Shen L - BMC Cancer (2015)

Kaplan-Meier survival curves of patients with ESCC according to treatment and c-Met expression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4307685&req=5

Fig4: Kaplan-Meier survival curves of patients with ESCC according to treatment and c-Met expression.
Mentions: In this study, 25 patients received chemotherapy of taxol and cisplatin (TP) plus nimotuzumab, 55 patients received chemotherapy of TP alone, and 10 patients received other chemotherapies. In c-Met overexpression group, OS of patients who received TP plus nimotuzumab was not different from that of patients who received TP alone (232d vs 258d, P = 0.221). Similar results were obtained in c-Met low-expression group (577d vs 422d, P = 0.152). In TP plus nimotuzumab group, the OS of patients with c-Met low-expression was significantly better than those with c-Met over-expression (577d vs 232d, P = 0.007). In TP alone group, no statistical significance was found (422d vs 258d, P = 0.076) (Figure 4).Figure 4

Bottom Line: There was no statistical difference between c-Met expression and clinical features except sex and tumor location.Survival analysis documented that the overexpression of c-Met predicted a worse prognosis (OS: 253 d vs 422 d, P = 0.011).The overexpression of c-Met may predict a worse efficacy of anti-EGFR therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, FuCheng Road 52, HaiDian District, Beijing, China. xyystella@163.com.

ABSTRACT

Background: c-Met, one of current potential hot targets, has been suggested as a potential tumor marker in the development of esophageal squamous cell carcinoma (ESCC). Our aim was to investigate the expression of c-Met in advanced esophageal squamous cell carcinoma in four phase II trials who had tumor tissues from archival in our center and analyze the correlations between c-Met expression and clinical features.

Methods: Ninety patients with advanced ESCC who were admitted to the phase II clinical trials in the Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute from March 2007 to March 2014 were finally eligible for present study and the corresponding tissues and clinical data were collected. The expression of c-Met in the tissue samples was detected by immunohistochemistry (IHC). c-Met overexpression was defined as ≥ the median value of H-score. Kaplan-Meier and Cox multivariate regression were conducted to evaluate the relationship between c-Met expression and ESCC survival.

Results: The overexpression of c-Met is 43.3% in advanced ESCC. There was no statistical difference between c-Met expression and clinical features except sex and tumor location. Survival analysis documented that the overexpression of c-Met predicted a worse prognosis (OS: 253 d vs 422 d, P = 0.011). In the group treated with chemotherapy combined with anti-EGFR drugs, patients with lowexpression of c-Met had a better OS than those with overexpression of c-Met (OS: 577 d vs 232 d, P = 0.007).

Conclusions: c-Met may be an independent prognostic factor in advanced ESCC. The overexpression of c-Met may predict a worse efficacy of anti-EGFR therapy.

Show MeSH
Related in: MedlinePlus